Annoying Psoriasis and Atopic Dermatitis: A Narrative Review

Int J Mol Sci. 2022 Apr 28;23(9):4898. doi: 10.3390/ijms23094898.

Abstract

Skin is an important organ that mainly functions as a barrier. Skin diseases can damage a person's self-confidence and reduce their willingness to socialize, as well as their social behavior and willingness. When the skin appearance is abnormal, in addition to affecting the quality of life, it often leads to personal, social, and psychological dysfunction and even induces depression. Psoriasis and atopic dermatitis are common chronic skin diseases. Their prevalence in the world is 3-10%, and there is an increasing trend year by year. These congenital or acquired factors cause the dysfunction of the immune system and then destroy the barrier function of the skin. Because these patients are flooded with a variety of inflammatory mediators, this causes skin cells to be in chronic inflammation. Therefore, psoriasis and atopic dermatitis are also considered systemic chronic inflammatory diseases. In the healthcare systems of developed countries, it is unavoidable to spend high costs to relieve symptoms of psoriasis and atopic dermatitis patients, because psoriasis and atopic dermatitis have a great influence on individuals and society. Giving a lot of attention and developing effective treatment methods are the topics that the medical community must work on together. Therefore, we used a narrative review manuscript to discuss pathogenesis, clinical classification, incidence, and treatment options, including topical medication, systemic therapeutics, immunosuppressive medication for psoriasis, and atopic dermatitis, as well as also comparing the differences between these two diseases. We look forward to providing readers with comprehensive information on psoriasis and atopic dermatitis through this review article.

Keywords: atopic dermatitis; psoriasis.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Dermatitis, Atopic* / drug therapy
  • Dermatitis, Atopic* / therapy
  • Humans
  • Psoriasis* / epidemiology
  • Psoriasis* / etiology
  • Psoriasis* / therapy
  • Quality of Life
  • Skin / pathology
  • Skin Diseases*

Grants and funding

This research was funded by National Science Council grant number [MOST 110-2320-B-038-062] in Taiwan.